Funder
National Natural Science Foundation of China
Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Shaik B, Zafar T, Balasubramanian K, Gupta SP. An Overview of Ovarian Cancer: Molecular Processes Involved and Development of Target-based Chemotherapeutics. Curr Top Med Chem. 2021;21(4):329–46.
2. Shoyab M, McDonald VL, Bradley JG, Todaro GJ. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci U S A. 1988;85(17):6528–32.
3. Singh B, Carpenter G, Coffey RJ: EGF receptor ligands: recent advances. F1000Res 2016;5:F1000 Faculty Rev–2270.
4. Nwani NG, Sima LE, Nieves-Neira W, Matei D. Targeting the Microenvironment in High Grade Serous Ovarian Cancer. Cancers (Basel). 2018;10(8):266.
5. Han C, Altwerger G, Menderes G, Haines K, Feinberg J, Lopez S, Manzano A, Varughese J, Santin AD. Novel targeted therapies in ovarian and uterine carcinosarcomas. Discov Med. 2018;25(140):309–19.